Further information Following collaboration with NHSE&I and Pfizer to establish the most appropriate route for the commissioning decision for the above technology. NICE have subsequently offered to ...

An isogenic cell line was created to model cancer patients with the echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion oncogene and tested for its ...

In December 2024, the FDA approved Ensacove as a first-line treatment for non-small-cell lung cancer ... of abnormal protein called anaplastic lymphoma kinase (ALK). In some cancers, this ...